Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Basel, 12 August 2022 - Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Children | Clinical Trials | Food and Drug Administration (FDA) | Influenza | New Drug Applications | Pharmaceuticals | USA Health